. Author manuscript; available in PMC: 2017 Jun 1.

Published in final edited form as: Hepatology. 2016 Mar 22;63(6):1796–1808. doi: 10.1002/hep.28497

Table 2.

Cost-effectiveness results.

	Mean incremental costs (£) per 10,000 prisoners^* [95% Interval]	Mean incremental QALYs per 10,000 prisoners^* [95% Interval]	Mean ICER (£ per QALY gained)
Double testing and provide status quo treatment	8,362,599^† [5,021,130–13,747,661]	421.27^† [172.93–789.53]	19,851^†
Double testing and provide 12 week IFN-free DAA therapy in prison	2,584,159^‡ [872,364–6,078,955]	171.25^‡ [46.89–396.74]	15,090^‡

^†

Compared to the status quo testing and treatment scenario.

^‡

Compared to the double testing and status quo treatment scenario.

We calibrate the model to 10,000 prisoners incarcerated at a given time (approximately 5,000,000 total individuals based on a 0.2% incarceration prevalence among the general population (15, 16)) and track individuals both in the community and those who cycle in/out of prison.